Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal vasculitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Retinal vasculitis. Displaying page 1 of 1.
    EudraCT Number: 2013-004668-71 Sponsor Protocol Number: 11/0499 Start Date*: 2014-09-25
    Sponsor Name:University College London
    Full Title: An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa
    Medical condition: Childhood systemic polyarteritis nodosa (PAN)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10036026 Polyarteritis nodosa of childhood LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004709-24 Sponsor Protocol Number: CERL080ANL05 Start Date*: 2007-03-20
    Sponsor Name:ErasmusMC
    Full Title: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.
    Medical condition: Uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001125-27 Sponsor Protocol Number: CL3-78989-002 Start Date*: 2013-01-15
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis EYEGUARD TM -B
    Medical condition: Behçet’s disease uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) GR (Prematurely Ended) PT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000754-97 Sponsor Protocol Number: OP/2017/6195 Start Date*: 2020-10-23
    Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust
    Full Title: Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial.
    Medical condition: Autoimmune non-infectious uveitis (ANIU)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075690 Autoimmune uveitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-000366-18 Sponsor Protocol Number: 2020/0420/HP Start Date*: 2022-08-18
    Sponsor Name:CHU de ROUEN
    Full Title: Efficacy and Tolerance of Baricitinib, a JAK inhibitor, in the treatment of refractory non-infectious uveitis
    Medical condition: Active non-anterior non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004853 10066681 Acute uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010327-41 Sponsor Protocol Number: EBEV Start Date*: 2010-02-23
    Sponsor Name:Fundació Privada Clínic per a la Recerca Biomèdica
    Full Title: Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravítreo en pacientes con edema macular uveítico
    Medical condition: Edema macular uveítico
    Disease: Version SOC Term Classification Code Term Level
    9 10046851 Uveitis PT
    9 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-009998-10 Sponsor Protocol Number: MYCUV-IIT02 Start Date*: 2010-02-24
    Sponsor Name:Centre for Ophthalmology, University of Tuebingen
    Full Title: Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial
    Medical condition: non-infectious uveitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002190-37 Sponsor Protocol Number: P140302 Start Date*: 2015-10-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC
    Medical condition: Behçet disease STELABEC-1: patients with oral ulcers STELABEC-2 : patients with active posterior uveitis or panuveitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011237-27 Sponsor Protocol Number: CAIN457C2303 Start Date*: 2009-10-15
    Sponsor Name:Novartis Pharma Services Ag
    Full Title: A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated ...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FR (Completed) DE (Completed) AT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006545-13 Sponsor Protocol Number: LX211-03-UV Start Date*: 2007-04-27
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.
    Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006543-31 Sponsor Protocol Number: LX211-01-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ...
    Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006544-66 Sponsor Protocol Number: LX211-02-UV Start Date*: 2007-04-13
    Sponsor Name:Lux Biosciences GmbH
    Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Qu...
    Medical condition: Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 16:37:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA